Illumina Debuts BioInsight Platform Unifying AI, Software, and Data

Illumina on October 14, 2026 debuted the Illumina BioInsight Platform, which the company describes as its first unified software environment for turning complex genomic and multiomic data into meaningful biological evidence.

The platform brings Illumina’s analysis applications, purpose-built AI models, and curated data resources together in one environment behind a single sign-on. Illumina said the consolidation reduces the need for researchers to assemble and manage separate informatics tools as their research questions evolve.

Rami Mehio, senior vice president and general manager of BioInsight at Illumina, said in the launch announcement that the platform brings customers “one simple place to access the full breadth of our offerings across software, AI, and data.” He added that customers using the BioInsight Platform will also gain access to new capabilities in the future.

According to Illumina, next-generation sequencing has expanded researchers’ ability to generate genomic and multiomic data, while the scale and complexity of those datasets have created a new challenge in turning data into insight efficiently. The company said AI has become an essential technology for quickly interpreting biological variation and prioritizing meaningful signals. Through the platform, researchers gain access to Illumina’s portfolio of genomic AI innovations, including SpliceAI2, the model for rare disease research that Illumina announced on October 8, 2026.

The BioInsight AI Lab, the research arm of the BioInsight business, applies multiomic data and AI to variant effect prediction, variant effect prioritization, and the training of biological foundation models. Illumina describes the models as purpose-built for genomics and said they help researchers identify, prioritize, and interpret biologically relevant signals across increasingly complex datasets, enabling deeper exploration of disease biology and genetic variation. The business also includes the Billion Cell Atlas program, which connects proprietary data with biopharma partners, and which Illumina said helps those partners connect genetic signals to cellular mechanisms and biological function.

DRAGEN V4.6 and the GP2 Parkinson’s Collaboration

Included with the platform is DRAGEN v4.6, the newly released version of Illumina’s secondary-analysis software. New deployment options, including a DRAGEN software mode, allow organizations to run DRAGEN across supported cloud and standard CPU environments. Illumina said data-residency requirements, infrastructure limitations, and operational needs can affect where and how genomic and multiomic analyses are performed, and that the new version delivers consistent analysis across supported compute environments.

Researchers are already using DRAGEN software mode to support large-scale genomic discovery efforts, according to the company. In collaboration with the Global Parkinson’s Genetics Program (GP2), a resource program of Aligning Science Across Parkinson’s in partnership with The Michael J. Fox Foundation for Parkinson’s Research, DRAGEN is supporting approximately 170 active research projects investigating the genetic basis of Parkinson’s disease. Illumina said faster processing and the ability to run analyses efficiently and consistently on a public cloud environment are helping GP2 accelerate and share its large genomic cohort studies.

Andrew Singleton of GP2 said software advances are crucial for a program driving research around the world, giving its researchers a consistent, comprehensive, and scalable environment for making sense of genetic data. He said the combination of speed and scalability lets the program concentrate on scientific questions rather than operational bottlenecks.

Curated Data and Usage-Based Pricing

The BioInsight Platform features curated datasets for research spanning oncology, rare disease, population health, and multiomics. Its BioInsight Data offering converts public and proprietary datasets into a harmonized, annotated, and reusable scientific catalog, and Illumina said the continuously updated datasets enable researchers to contextualize findings across studies, generate new hypotheses, and accelerate biological discovery.

The platform consolidates Illumina’s informatics applications: DRAGEN, Emedgene, Connected Multiomics, BioInsight Platform Core, BaseSpace, and BioInsight Data. A usage-based BioInsight Credits model replaces traditional annual subscriptions, which Illumina said lets researchers adopt the capabilities most relevant to their work while retaining flexibility to evaluate new technologies as scientific needs evolve. The company said researchers can sign up for a free trial of the platform.

The BioInsight Business and ASHG 2026 Showcase

Illumina’s BioInsight business unit was created one year before the platform’s debut to address the gap between data generation and biological insight. Illumina formed the business on October 1, 2025, saying it was developed to meet industry demand for deeper biological insights as researchers and pharmaceutical companies sought to access and interpret ever-larger multiomic datasets. At launch, Illumina defined four focus areas for the unit: enabling large-scale genetic and biological data generation projects with large national initiatives and industry partners; developing software to analyze multimodal data at population scale; providing platforms for private and secure data access for research and pharmaceutical partners; and developing AI tools through strategic partnerships.

Illumina chief executive Jacob Thaysen said in the October 2025 announcement that BioInsight, under Mehio’s guidance, “will strengthen Illumina’s leadership at the intersection of sequencing, software, and AI, with a focus on supporting pharma in drug target discovery and development.” Mehio has led BioInsight as senior vice president and general manager since its creation; he previously spent four years leading Illumina’s Global Software & Informatics team and joined the company’s executive leadership team when the unit was announced.

Illumina will showcase the BioInsight Platform at the American Society for Human Genetics annual meeting in Montreal, where it will exhibit at booth 701. Illumina’s ASHG 2026 events page dates the meeting to October 20–24, 2026 at the Palais des Congrès de Montréal. Mehio is scheduled to speak in an Industry Education session on biological discovery at scale on October 23, 2026, and Illumina will hold a DRAGEN user group meeting in Montreal on October 22, 2026.